Avadel Pharmaceuticals Plc (NASDAQ: AVDL) has announced its preliminary 2024 results and 2025 commercial priorities to accelerate the Lumryz launch. The key financial highlights include a significant ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

In a recent transaction reported to the Securities and Exchange Commission, Linda Palczuk, a director at Avadel ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev ...

"Providing comprehensive support to patients and providers and continuously improving their experience with LUMRYZ is critical to Avadel’s success. Sev’s expertise in establishing and leading patient ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings ...

ADMA had a big year in 2024; as it moved toward increased commercialization of some of its products, revenue and net income ...

Lumryz (sodium oxybate) is a brand-name oral liquid prescribed for narcolepsy in adults and certain children. As with other drugs, Lumryz can cause side effects, such as dizziness, nausea ...

Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

Lumryz (sodium oxybate) is a brand-name oral suspension that’s prescribed for symptoms of narcolepsy in adults. Lumryz has interactions with alcohol, some other drugs, and certain supplements.

LUMRYZ is sodium oxybate ER oral suspension used in narcolepsy patients with 7 years of age or older for the treatment of cataplexy or EDS. In April 2024, Harmony Biosciences Holdings, Inc. started ...